Business Wire

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results | Business Wire

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout ...
Business Wire

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore ...
Nasdaq

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that ...
Nasdaq

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023 Reports Cash and Cash Equivalents of $124.8M, Providing Runway ...